Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Marinus Pharma CS (MRNS)

Marinus Pharma CS (MRNS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 18,448
  • Shares Outstanding, K 55,084
  • Annual Sales, $ 30,990 K
  • Annual Income, $ -141,410 K
  • EBIT $ -135 M
  • EBITDA $ -135 M
  • 60-Month Beta 1.26
  • Price/Sales 0.58
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.63
  • Most Recent Earnings $-0.60 on 08/13/24
  • Next Earnings Date 11/05/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 337.00% ( -35.35%)
  • Historical Volatility 516.18%
  • IV Percentile 92%
  • IV Rank 52.81%
  • IV High 618.48% on 09/06/24
  • IV Low 22.02% on 07/12/24
  • Put/Call Vol Ratio 0.05
  • Today's Volume 20
  • Volume Avg (30-Day) 1,065
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 23,360
  • Open Int (30-Day) 20,847

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.44
  • Number of Estimates 5
  • High Estimate -0.40
  • Low Estimate -0.47
  • Prior Year -0.61
  • Growth Rate Est. (year over year) +27.87%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2603 +37.84%
on 10/25/24
1.9600 -81.69%
on 10/21/24
-1.4912 (-80.61%)
since 10/07/24
3-Month
0.2603 +37.84%
on 10/25/24
1.9700 -81.79%
on 09/24/24
-0.8012 (-69.07%)
since 08/07/24
52-Week
0.2603 +37.84%
on 10/25/24
11.2600 -96.81%
on 01/08/24
-6.1512 (-94.49%)
since 11/07/23

Most Recent Stories

More News
3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity

Check out these three micro-cap stocks that show big-time potential upside, but also pose face large obstacles to achieving success.

IWC : 134.62 (-0.25%)
LODE : 0.3923 (+6.03%)
AMPX : 1.3100 (+3.97%)
SPY : 594.63 (+0.61%)
MRNS : 0.3630 (+8.39%)
Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?

Marinus is an under $2 biotech stock with Wall Street analysts price targets ranging from $2 to $13. Its upcoming trial results have big implications.

MRNS : 0.3630 (+8.39%)
Marinus Pharmaceuticals: Q2 Earnings Snapshot

Marinus Pharmaceuticals: Q2 Earnings Snapshot

MRNS : 0.3630 (+8.39%)
Marinus Pharmaceuticals: Q1 Earnings Snapshot

Marinus Pharmaceuticals: Q1 Earnings Snapshot

MRNS : 0.3630 (+8.39%)
Marinus Pharmaceuticals: Q4 Earnings Snapshot

Marinus Pharmaceuticals: Q4 Earnings Snapshot

MRNS : 0.3630 (+8.39%)
Marinus Pharmaceuticals: Q3 Earnings Snapshot

Marinus Pharmaceuticals: Q3 Earnings Snapshot

MRNS : 0.3630 (+8.39%)
Marinus Pharmaceuticals: Q2 Earnings Snapshot

Marinus Pharmaceuticals: Q2 Earnings Snapshot

MRNS : 0.3630 (+8.39%)
Marinus Pharmaceuticals: Q1 Earnings Snapshot

Marinus Pharmaceuticals: Q1 Earnings Snapshot

MRNS : 0.3630 (+8.39%)
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will present...

MRNS : 0.3630 (+8.39%)
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 11, 2023

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial...

MRNS : 0.3630 (+8.39%)

Business Summary

Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical...

See More

Key Turning Points

3rd Resistance Point 0.3854
2nd Resistance Point 0.3654
1st Resistance Point 0.3501
Last Price 0.3630
1st Support Level 0.3148
2nd Support Level 0.2948
3rd Support Level 0.2795

See More

52-Week High 11.2600
Fibonacci 61.8% 7.0581
Fibonacci 50% 5.7601
Fibonacci 38.2% 4.4622
Last Price 0.3630
52-Week Low 0.2603

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar